The 2-lysophosphatidylcholine analog edelfosine induces apoptosis in highly proliferating cells, e.g. activated immune cells. We examined mechanisms of action of edelfosine on immune functions in experimental autoimmune encephalomyelitis, a well-accepted animal model for multiple sclerosis. We observed activated caspase-3 expression in lymphoid organs and the central nervous system; however, edelfosine did not induce global apoptosis. Edelfosine improved the disease course and led to reduced frequencies of CD4 + T cells infiltrating into the central nervous system. Our data suggest edelfosine as an interesting treatment candidate for multiple sclerosis.
Introduction
Apoptotic cell death is an elementary cellular response and involves the sequential activation of caspases. The stress-inducible, intrinsic apoptotic pathway involves cytochrome c release from mitochondria (Liu et al., 1996) . The extrinsic pathway is induced by pro-apoptotic and pro-inflammatory cytokines, e.g. FasL, TRAIL and TNF-α, respectively, which induce the intracellular formation of specific death-inducing signaling complexes (DISCs) after binding to death domain receptors (Scaffidi et al., 1999; Micheau and Tschopp, 2003) . Downstream caspases, e.g. caspase-3, are cleaved to execute cell death. Importantly, elimination of cells via apoptosis does not lead to inflammation or immune activation. Therefore, approaches to induce apoptosis in deregulated, e.g. self-reactive immune cells have been considered to treat autoimmune diseases, for instance multiple sclerosis (MS).
Many potentially pathogenic factors and disease mechanisms have been examined in animal models, particularly in experimental autoimmune encephalomyelitis (EAE) (Raine et al., 1980) , and both animal and human studies point to a central role for autoreactive CD4 + T cells in MS pathology (Sospedra and Martin, 2005) . CD4 + T cells are present in central nervous system (CNS) and cerebrospinal fluid (CSF) cellular infiltrates in both MS and EAE (Pettinelli and McFarlin, 1981; Richert et al., 1983; Martin et al., 1990; Ota et al., 1990) . Further, albeit indirect evidence for their role stems from the observation that a large fraction of the genetic risk of MS is conferred by HLA-class II alleles of the HLA-DR15 haplotype (Jersild et al., 1973; Hillert and Olerup, 1993) . Recently published large genome-wide association studies show over 130 single nucleotide polymorphisms besides HLA-DR as risk alleles for MS (Sawcer et al., 2011; Beecham et al., 2013) , and interestingly many of these are involved in T cell activation and function (Lundmark et al., 2007; McElroy and Oksenberg, 2008 
